电治疗后的迟发性发作:患病率和相关因素
Rania Lansari1, Karim Souabni1, Yosra Ben Nasr1
1University of Tunis El Manar, Faculty of Medicine of Tunis, Department of Psychiatry D, Razi Hospital, Manouba, Tunisia.
L'Encephale
|November 24, 2024
概括
电疗法 (ECT) 后的迟发性发作很少见,影响了本研究中的4.45%的患者. 管理风险因素是预防这些晚发性发作的关键.
科学领域:
- 神经学 神经学
- 精神病学是一个精神病学.
- 临床神经生理学 临床神经生理学
背景情况:
- 迟发性,一种罕见的电治疗后 (ECT) 事件,可能导致严重的并发症,如状态.
- 了解风险因素和晚发性的患病率对于ECT期间的患者安全至关重要.
- 关于晚发作的数据有限,这凸显了进一步研究和数据共享的必要性.
研究的目的:
- 为了确定在急性治疗阶段电治疗 (ECT) 后晚发作发作的患病率.
- 为了确定与ECT后晚期发作的发生相关的变量.
- 为未充分探索的ECT后发作领域提供数据.
主要方法:
- 一项描述性,回顾性研究分析了突尼斯的一家ECT单位 (2015年12月 - 2023年9月) 的医疗记录.
- 包括157名患者的1931个ECT会话,在初始治疗过程中提供EEG跟踪.
- 通过ECT后的自发运动表现来定义晚期,同时有意识变化和模两可的EEG发现.
主要成果:
- 在157名患者中,有7名患者 (4.45%) 经历过至少一次晚期发作.
- 在1931年的会议中记录了11次晚期发作,患病率为0.57%.
- 相关因素包括男性性别,神经病变,发性值降低疗法,埃托米达麻醉,值附近的刺激电荷,长时间诱导的发作和发作后脑电图抑制不良.
结论:
- 电电疗法后的迟发性是罕见的不良事件,尽管现有的文献有限.
- 建议对已识别的风险因素进行主动管理,以预防晚发性发作.
- 进一步的研究和数据共享对于更好地理解和管理这种现象至关重要.
关键词:
危机性抽性发作危机晚期的危机.不良影响不良效应.电疗法是一种电疗法.电脑脑电图 (EEG) 是一种电脑电图.发作 发作 发作副作用 副作用 副作用 副作用晚期性发作 晚期性发作电疗法是一种电疗法.一个电脑电图.更多相关视频
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
12.0K
08:20MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
13.8K
相关概念视频
Electroconvulsive Therapy
25
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
25
Arteries of the Lower Limbs
177
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
177
Seizures: Classification
302
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
302
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
251
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
251
